Protein tyrosine kinases as new potential targets against human schistosomiasis
Protein tyrosine kinases as new potential targets against human schistosomiasis
复制标题
DOI：
10.1002/bies.20662
复制
发表时间：
2007-12-01
期刊：
影响因子：
4
通讯作者：
Khayath, Naji
中科院分区：
文献类型：
--
作者：
Dissous, Colette;Ahier, Arnaud;Khayath, Naji
尽管为控制其传播作出了许多努力，但寄生虫寄生虫体仍然是许多发展中国家严重的公共卫生问题和主要的经济问题。吡喹酮（PZQ）是治疗血吸虫病的首选药物，也是唯一一种可用于大规模化疗的药物。然而，它的广泛使用及其对幼年寄生虫的无效性引起了人们对寄生虫体将产生耐药性的担忧，并使得替代药物的开发非常可取。蛋白酪氨酸激酶（PTKs）是控制细胞分化和增殖的关键分子，它们已经成为分子癌症治疗的重要靶点。最近在曼氏血吸虫的几个胞质和受体PTKs的特性，类似的，但也不同于他们的脊椎动物同行，开辟了新的视角，在血吸虫病的化疗，这可能是基于使用寄生虫特异性酪氨酸磷酸化抑制剂的新策略的发展。
In spite of the numerous efforts made to control their transmission, parasite schistosomes still represent a serious public health concern and a major economic problem in many developing countries. Praziquantel (PZQ) is the drug of choice for the treatment of schistosomiasis and the only one that is available for mass chemotherapy. However, its widespread use and its inefficacy on juvenile parasites raise fears that schistosomes will develop drug resistance, and make the development of alternative drugs highly desirable. Protein tyrosine kinases (PTKs) are key molecules that control cell differentiation and proliferation and they already represent important targets for molecular cancer therapy. The recent characterization in Schistosoma mansoni of several cytosolic and receptor PTKs, with properties similar but also divergent from their vertebrate counterparts, opens new perspectives for the development of novel strategies in chemotherapy of schistosomiasis, which could be based on the use of parasite-specific tyrosine phosphorylation inhibitors.